Взаимосвязь между генетическими предикторами и уровнем ферритина при метаболическом синдроме
DOI:
https://doi.org/10.54500/2790-1203-2024-4-124-80-86Ключевые слова:
метаболический синдром, гиперферритинемия, генный предиктор, инсулинорезистентность, полиморфизм геновАннотация
Метаболический синдром определяется как патологическое состояние, характеризующееся абдоминальным ожирением, инсулинорезистентностью, гипертонией и гиперлипидемией. Хотя успешное завоевание инфекционных заболеваний во всем мире было осуществлено, это новое неинфекционное заболевание представляет серьезную угрозу для здоровья современного мира.
Гиперферритинемия в патогенезе метаболического синдрома запускает каскад механизмов участвующих в развитии инсулинорезистентности, стеатоза/фиброза печени и т.д. В ходе специальных исследований была доказана роль пяти ключевых генов в развитии гиперферритинемии: HFE (гемохроматоз), HJV (гемоювелин), HAMP (антимикробный пептид гепсидина), TfR2 (рецептор трансферрина 2) и FP (ферропортин).
Определение взаимосвязи и генных предикторов между гиперферритинемией и компонентами метаболического синдрома способствует тому, что в настоящее время врачи начали проводить персонализированное лечение для каждого пациента.
Скачивания
Библиографические ссылки
Sachinidis A., Doumas M., Imprialos K., Stavropoulos K. et al. Dysmetabolic iron overload in metabolic syndrome. Current pharmaceutical design, 2020; 26(10): 1019-1024.
Saklayen M.G. The global epidemic of the metabolic syndrome. Current hypertension reports, 2018; 20(2): 1-8.
Богданова О.Г., Мыльникова И.В. Метаболический синдром: ситуация в мире, клинико-диагностические критерии и факторы риска //Гигиена и санитария. - 2020. - Т. 99. - №10. - С. 1165-1169.
Bogdanova O.G., My`l`nikova I.V. Metabolicheskij sindrom: situaciya v mire, kliniko-diagnosticheskie kriterii i faktory` riska (Metabolic syndrome: global situation, clinical and diagnostic criteria and risk factors) [in Russian]. Gigiena i sanitariya, 2020; 99(10): 1165-1169.
Al Akl N.S., Khalifa O., Errafii K., Arredouani A. Association of dyslipidemia, diabetes and metabolic syndrome with serum ferritin levels: a middle eastern population-based cross-sectional study. Scientific Reports, 2021; 11(1): 24080.
Nguyen H.D., Ardeshir A., Fonseca V.A., Kim W.K. Cluster of differentiation molecules in the metabolic syndrome. Clinica Chimica Acta, 2024; 119819.
Альмуханова А.Б., Раисова А.Е., Зайнутдинова Н.Р., Зинбай Ф.А. Распространенность метаболического синдрома у детей и подростков //Вестник Казахского Национального медицинского университета. - 2021. - №1. - с. 78-80.
Al`muxanova A.B., Raisova A.E., Zajnutdinova N.R., Zinbaj F.A. Rasprostranennost` metabolicheskogo sindroma u detej i podrostkov (Prevalence of metabolic syndrome in children and adolescents) [in Russian]. Vestnik Kazaxskogo Nacional`nogo medicinskogo universiteta, 2021; 1: 78-80.
Tursynbekova A.E., Karibaev K.R. Tokmurzieva G.Zh., Kulzhanov M.K. Prevalence of metabolic syndrome and its main components in the civil servants of Almaty. Journal Medicine, 2018; 192(6): 9-15.
Kahn C.R., Wang G., Lee K.Y. Altered adipose tissue and adipocyte function in the pathogenesis of metabolic syndrome. The Journal of clinical investigation, 2019; 129(10): 3990-4000.
Varra F.N., Varras M., Varra V.K., Theodosis-Nobelos P. Molecular and pathophysiological relationship between obesity and chronic inflammation in the manifestation of metabolic dysfunctions and their inflammation mediating treatment options. Molecular Medicine Reports, 2024; 29(6): 95.
De Gobbi M., Roetto A., Piperno A., Mariani R. et al. Natural history of juvenile haemochromatosis. British journal of haematology, 2002; 117(4): 973-979.
Hsu C.N., Hou C.Y., Hsu W.H., Tain Y.L. Early-life origins of metabolic syndrome: mechanisms and preventive aspects. International journal of molecular sciences, 2021; 22(21): 11872.
Litwin M., Kułaga Z. Obesity, metabolic syndrome, and primary hypertension. Pediatric Nephrology, 2021; 36(4): 825-837.
Gesteiro E., Megía A., Guadalupe-Grau A., Fernandez-Veledo S. et al. Early identification of metabolic syndrome risk: A review of reviews and proposal for defining pre-metabolic syndrome status. Nutrition, Metabolism and Cardiovascular Diseases, 2021; 31(9): 2557-2574.
Piperno A., Pelucchi S., Mariani R. Inherited iron overload disorders. Translational gastroenterology and hepatology, 2020; 5.
Shi Y., Zou Y., Shen Z., Xiong Y. et al. Trace elements, PPARs, and metabolic syndrome. International journal of molecular sciences, 2020; 21(7): 2612.
Klip I.T., Voors A.A., Swinkels D.W., Bakker S.J. et al. Serum ferritin and risk for new‐onset heart failure and cardiovascular events in the community. European Journal of Heart Failure, 2017; 19(3): 348-356.
Chen L., Li Y., Zhang F., Zhang S. et al. Elevated serum ferritin concentration is associated with incident type 2 diabetes mellitus in a Chinese population: A prospective cohort study. Diabetes research and clinical practice, 2018; 139: 155-162.
Balla J., Balla G., Zarjou A. Ferritin in kidney and vascular related diseases: novel roles for an old player. Pharmaceuticals, 2019; 12(2): 96.
Hayakawa M., Hattori K., Sugiyama S., Ozawa T. Age-associated oxygen damage and mutations in mitochondrial DNA in human hearts. Biochemical and biophysical research communications, 1992; 189(2): 979-985.
Barciszewski J., Barciszewska M.Z., Siboska G., Rattan S.I. et al. Some unusual nucleic acid bases are products of hydroxyl radical oxidation of DNA and RNA. Molecular Biology Reports, 1999; 26: 231-238.
Hudish L.I., Reusch J.E., Sussel L. β Cell dysfunction during progression of metabolic syndrome to type 2 diabetes. The Journal of clinical investigation, 2019; 129(10): 4001-4008.
Zhang W.C.B., Yang X.I.N.G., Bing S.H.A.O. Serum ferritin and the risk of metabolic syndrome: a systematic review and dose-response meta-analysis of cross-sectional studies. Biomedical and Environmental Sciences, 2021; 34(8): 623-631.
Salonen J.T., Nyyssönen K., Korpela H., Tuomilehto J. et al. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation, 1992; 86(3): 803-811.
Li J., Bao W., Zhang T., Zhou Y. et al. Independent relationship between serum ferritin levels and dyslipidemia in Chinese adults: a population study. PLoS One, 2017; 12(12): e0190310.
Klip I.T., Voors A.A., Swinkels D.W., Bakker S.J. et al. Serum ferritin and risk for new‐onset heart failure and cardiovascular events in the community. European Journal of Heart Failure, 2017; 19(3): 348-356.
Valenti L., Corradini E., Adams L.A., Aigner E. et al. Consensus Statement on the definition and classification of metabolic hyperferritinaemia. Nature Reviews Endocrinology, 2023; 19(5): 299-310.
Corradini E., Buzzetti E., Pietrangelo A. Genetic iron overload disorders. Molecular aspects of medicine, 2020; 75: 100896.
Kalluru P.K.R., Mamilla M., Valisekka S.S., Mandyam S. et al. Aminotransferases in relation to the severity of dengue: a systematic review. Cureus, 2023; 15(5).
European Association for the Study of the Liver. EASL clinical practice guidelines on haemochromatosis. Journal of hepatology, 2022; 77(2): 479-502.
Alexander J., Kowdley K.V. Hereditary hemochromatosis: genetics, pathogenesis, and clinical management. Annals of hepatology, 2005; 4(4): 240-247.
Castiella A., Zapata E., Zubiaurre L., Alustiza J.M. et al. Impact of H63D mutations, magnetic resonance and metabolic syndrome among outpatient referrals for elevated serum ferritin in the Basque Country. Annals of Hepatology, 2015; 14(3): 333-339.
Xiao Y., Zhu C., Jiang F., Gao Q. et al. Novel ceruloplasmin gene mutation causing aceruloplasminemia with diabetes in a Chinese woman: a case report. Annals of Palliative Medicine, 2022; 11(7): 2516522-2512522.
Xu W.Q., Ni W., Wang R.M., Dong Y. et al. A novel ceruloplasmin mutation identified in a Chinese patient and clinical spectrum of aceruloplasminemia patients. Metabolic Brain Disease, 2021; 36(8): 2273-2281.
Zhang X., Zuo R., Xiao S., Wang L. Association between iron metabolism and non-alcoholic fatty liver disease: results from the National Health and Nutrition Examination Survey (NHANES 2017–2018) and a controlled animal study. Nutrition & Metabolism, 2022; 19(1): 81.
Horniblow R.D., Pathak P., Balacco D.L., Acharjee A. et al. Iron-mediated epigenetic activation of NRF2 targets. The Journal of Nutritional Biochemistry, 2022; 101: 108929.
Valenti L., Maggioni P., Piperno A., Rametta R. et al. Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis. World Journal of Gastroenterology: WJG, 2012; 18(22): 2813.
Stickel F., Buch S., Zoller H., Hultcrantz R. et al. Evaluation of genome-wide loci of iron metabolism in hereditary hemochromatosis identifies PCSK7 as a host risk factor of liver cirrhosis. Human molecular genetics, 2014; 23(14): 3883-3890.
Kim J., Woo H.W., Shin M.H., Kim Y.M. et al. Genome-wide gene and serum ferritin interaction in the development of type 2 diabetes in adults aged 40 years or older. Nutrition, Metabolism and Cardiovascular Diseases, 2022; 32(1): 231-240.
Moksnes M.R., Graham S.E., Wu K.H., Hansen A.F. et al. Genome-wide meta-analysis of iron status biomarkers and the effect of iron on all-cause mortality in HUNT. Communications Biology, 2022; 5(1): 591.
